Region — US. Neutral scientific reference — not offered for sale here.
Research reference — not for sale
Small molecule (non-peptide)
also called — orforglipron (or-for-GLIP-ron) · Lilly code LY3502970 · Chugai code OWL833
metabolicobesity / weighttype-2 diabetes (investigational)
Reference entry — NOT a sellable lane, NOT yet approved. Potentially the most consequential drug in this whole register — not because it's the strongest, but because it's the first oral small-molecule GLP-1, which could solve the class's cost-and-supply problem. NDA for obesity submitted Dec 2025. N
In brief
Orforglipron is the first oral small-molecule GLP-1 — a non-peptide pill, taken anytime without food/water restrictions, that in Phase 3 delivered semaglutide-level weight loss (~11–12%) and solid glycemic control. Its significance is less about the size of the effect than about manufacturing and access: a cheaply mass-produced oral GLP-1 that Lilly says it can supply worldwide without constraint. Lilly filed the obesity NDA in December 2025; it is not yet approved.
Legal standing, by region
- Everywhere — investigational, not approved. Obesity NDA submitted to the FDA (Dec 2025); T2D filing expected 2026. A potential 2026 approval would make it the first oral small-molecule GLP-1.
- Gray market: because it's a small molecule (easier to synthesise than a peptide), unregulated "research orforglipron" copies may proliferate faster than peptide knock-offs — and are just as unapproved and
Evidence, by outcome
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
OutcomeEvidence base · effectGrade
Weight loss (obesity)
Strong Phase 3 and FDA-filed, but not yet approved; efficacy is semaglutide-level, not tirzepatide-level
Phase 3 ATTAIN-1 (NEJM 2025, ~11–12%); NDA filed Dec 2025 · Meaningful; semaglutide-like
BType-2 diabetes glycemic control
Phase 3 complete/near-complete; T2D filing 2026; not yet approved
Phase 3 ACHIEVE programme (5 trials, superior A1C; NEJM 2025) · Robust, foundational
BWeight maintenance after injectables
First-of-its-kind; topline
ATTAIN-MAINTAIN (Dec 2025) · Maintained (switch from Wegovy/Zepbound)
BManufacturing / access advantage
The reason it may matter more than its weight-loss number
Small-molecule chemistry · Cheap, scalable, no cold chain, no food/water ritual
—Safety
Class-typical GI effects; investigational
Phase 3 (GI-predominant) · Consistent with the GLP-1 class
—Identity an investigational, once-daily small-molecule (non-peptide) oral GLP-1 receptor agonist — and, critically, one that can be taken any time of day with no food or water restrictions. Discovered by Chugai Pharmaceutical (Japan) and licensed by Lilly in 2018; the two published its preclinical pharmacology together. ## Mechanism (as proposed) a small-molecule agonist of the GLP-1 receptor (with biased/partial-agonist pharmacology distinct from the peptide full agonists) → the familiar GLP-1 effects (glucose-dependent insulin, glucagon suppression, slowed gastric emptying, reduced appetite). The novelty is not the target but the chemistry — a non-peptide that survives oral dosing without absorption enhancers or a dosing ritual, and that can be manufactured like a conventional tablet.
Sources — 3 cited
01Eli Lilly — ACHIEVE-1 (NEJM, 2025); ATTAIN-1 (NEJM, Sept 2025); ATTAIN-MAINTAIN topline (Dec 2025); ACHIEVE-2/-5 (Oct 2025); head-to-head vs oral semaglutide.
02Chugai / Lilly — preclinical pharmacology of orforglipron (OWL833 / LY3502970).
03Lilly — obesity NDA submission and Commissioner's National Priority Voucher (Dec 2025).
Review status
Not yet reviewed
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (fast-moving — re-check the FDA obesity decision and T2D filing).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
VallydiaA neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
Region — United States
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.